74 A new study published in BBA – Reviews on Cancer has unveiled significant advancements in the understanding of cervical cancer, highlighting the role of molecular biomarkers and genetic alterations. This research paves the way for precision medicine approaches, offering hope for improved diagnostics, targeted therapies, and ultimately better patient outcomes. The study identifies several promising biomarkers that can significantly enhance the early detection of cervical cancer. Traditional methods, such as Pap smears, have been instrumental in reducing the incidence and mortality of cervical cancer, but they are not infallible. By focusing on molecular biomarkers, researchers are aiming to improve the sensitivity and specificity of cervical cancer screening. One of the key findings is the identification of HPV DNA, p16, and Ki67 as critical biomarkers. The presence of HPV DNA, particularly high-risk types like HPV16 and HPV18, is strongly associated with cervical cancer development. The overexpression of p16, a protein associated with HPV-induced transformation, and Ki67, a marker of cell proliferation, provides additional layers of diagnostic precision, enabling the detection of pre-cancerous lesions with greater accuracy. Cervical cancer is driven by complex molecular pathways and genetic alterations. Understanding these pathways is crucial for developing targeted therapies. The study highlights several key pathways implicated in cervical cancer progression: PI3K/Akt/mTOR pathway. This pathway, which regulates cell growth and survival, is frequently activated in cervical cancer. Genetic alterations such as PIK3CA mutations and PTEN loss lead to its activation, promoting tumour progression and resistance to treatment . HPV pathway. Persistent infection with high-risk HPV types disrupts cellular processes through viral oncoproteins E6 and E7, which degrade tumour suppressor proteins p53 and pRb, leading to uncontrolled cell proliferation . Wnt/β-catenin pathway. This pathway regulates cell proliferation and differentiation. Its dysregulation is observed in cervical cancer, contributing to tumour invasion and metastasis. The study also explores the advances in high-throughput technologies that have revolutionised the field of cancer research. Techniques such as next-generation sequencing (NGS), RNA sequencing (RNA-seq), and mass spectrometry-based proteomics provide comprehensive insights into the molecular alterations driving cervical cancer. Genomic technologies. Whole-genome sequencing (WGS) and whole-exome sequencing (WES) allow for the detailed analysis of genetic mutations, copy number variations (CNVs), and structural rearrangements. These techniques have identified key driver mutations in genes such as PIK3CA and TP53, which are crucial for understanding tumour biology and developing targeted therapies. Transcriptomic technologies. RNA-seq facilitates the analysis of gene expression patterns and identifies dysregulated genes and signalling pathways involved in cervical carcinogenesis. This technology also helps in discovering alternative splicing events and non-coding RNAs, which add complexity to the cancer transcriptome and serve as potential biomarkers . Proteomic technologies. Mass spectrometry-based techniques enable the quantitative analysis of protein expression and post-translational modifications. This approach helps in understanding protein-protein interactions and identifying protein biomarkers that are critical for cancer diagnostics and therapeutics . Despite the promising advancements, several challenges remain in translating these findings into clinical practice. Tumour heterogeneity, resistance to treatment, and limited access to molecular testing infrastructure pose significant obstacles. The study underscores the need for sustained investment in translational research, clinical validation, and the development of cutting-edge technologies. Interdisciplinary cooperation among clinicians, researchers, industry stakeholders, and policymakers is essential to unlock the full potential of precision medicine in cervical cancer. As our understanding of cervical cancer biology deepens, the integration of biomarker-guided diagnostics and targeted therapies into clinical settings is expected to transform patient care, offering more personalised and effective treatment options.